Skin health and disease
Cure8 research brief
Why This Matters
A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.
Who Should Pay Attention
Patients with refractory PG; people with Crohn disease and skin complications; clinicians prescribing biologics; researchers of IL‑23 therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
A 26‑year‑old woman with PG later developed Crohn disease and had inadequate response to azathioprine, infliximab, and ustekinumab. Corticosteroids were restarted and subcutaneous guselkumab was begun. The authors report complete ulcer healing after the second dose and maintenance of remission for over two years on guselkumab monotherapy.
The report adds to case‑level evidence that IL‑23 inhibitors can help treatment‑resistant PG, particularly when associated with IBD; however, it is a single‑patient case report, not a controlled trial.
Keep In Mind
This is a case report published in a dermatology journal and summarized as an abstract on PubMed. It describes one patient’s course and sustained remission for over two years but does not provide controlled trial data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationSkin health and disease
AuthorsMahmut Esat Tanrıbilir, Osmanege Atliya, Tarkan Karakan +1 more
InstitutionDepartment of Dermatology, Ministry of Health Ilgın Dr. Vefa Tanır State Hospital, Konya, Turkey.
Study typeCase reports, journal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 8, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: The authors declare no conflicts of interest. Data availabilityData sharing is not applicable to this article as no datasets were generated or analysed during the current study.Ethics statementNot applicable.Patient consentWritten patient consent for publication was obtained.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Medical Therapies Beyond Infliximab for Perianal Fistulizing Crohn's Disease: Current Evidence and Future Perspectives.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...